Harrow
Andrew Thorrens has a strong background in the pharmaceutical and healthcare industry, with extensive experience in market access, pricing, trade, and distribution. Andrew is currently the Vice President and Head of Market Access, Pricing, Trade, and Distribution at Harrow, starting in March 2022. Prior to this, they served as an Investor & Clinical Advisory Board Member at PhotoniCare, Inc. from July 2014 to March 2022. Andrew also held the role of Head of Commercial Operations/Market Access at Cidara Therapeutics from February 2020 to July 2021. Andrew has held various leadership positions in market access and reimbursement at companies such as Xeris Pharmaceuticals, Allergan, Takeda, and Baxter International Inc. Overall, they have over three decades of experience in the industry.
Andrew Thorrens attended Stanford University and the University of Southern California, but there is no information available about the specific degrees or fields of study they pursued at these institutions.
This person is not in any offices
Harrow
2 followers
Harrow (Nasdaq: HROW) is a leading U.S. eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic prescription therapies that are accessible and affordable. Harrow owns U.S. commercial rights to ten FDA-approved ophthalmic pharmaceutical products. Harrow also owns and operates ImprimisRx, the leading U.S. ophthalmic‑focused pharmaceutical compounding business, which also serves as a mail-order pharmacy licensed to ship prescription medications in all 50 states. Harrow has non-controlling equity positions in Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc., companies that began as subsidiaries of Harrow. Harrow also owns royalty rights in four late-stage drug candidates being developed by Surface and Melt.